Back to top
more

ProPhase Labs (PRPH)

(Delayed Data from NSDQ)

$1.43 USD

1.43
215,099

-0.51 (-26.29%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $1.42 -0.01 (-0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

NortonLifeLock (NLOK) to Report Q4 Earnings: What to Expect?

by Zacks Equity Research

NortonLifeLock's (NLOK) Q4 results are likely to reflect increased digital security demand amid the pandemic-led work-from-home and online learning trend.

All You Need to Know About ProPhase Labs, Inc. (PRPH) Rating Upgrade to Strong Buy

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What to Expect From Centene (CNC) this Earnings Season?

by Zacks Equity Research

Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.

Zacks.com featured highlights ProPhase Labs, Hudson Technologies and YPF Sociedad Anonima

by Zacks Equity Research

ProPhase Labs, Hudson Technologies and YPF Sociedad Anonima have been highlighted in this Screen of the Week article.

Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs?

by Zacks Equity Research

Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.

Tirthankar Chakraborty headshot

3 Top Breakout Stocks to Buy for Remarkable Returns

by Tirthankar Chakraborty

ProPhase Labs (PRPH), Hudson Technologies (HDSN) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.

Anthem (ANTM) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Anthem's (ANTM) first-quarter results are likely to benefit from the growing premiums and an uptick in Medicare and Medicaid membership, partly offset by higher expenses.

bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn

by Zacks Equity Research

bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.

Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August

by Zacks Equity Research

Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.

    Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study

    by Zacks Equity Research

    Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.

      ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?

      by Zacks Equity Research

      ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.